EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Using GLP-1 Receptor Agonists in Patients with Inflammatory Bowel Disease: A Systematic Review and Single-Arm Meta-Analysis

Omar Khasawneh, Kyrillos Mahrous Gerges, Islam Khasawneh, Edoardo V. Savarino, Brigida Barberio, Ahmed Farid Gadelmawla, Basma Mansor Elhabbasi, Maram Albandak, Abdelmoneim Taher Mohamed, Hala Abubkr Shlibek, Bisher Sawaf, Miguel Regueiro, Muhammed Elhadi

Digestive Diseases · 2026-08-18 · 1-24

DOI: 10.1159/000553479 ↗
AbstractBibliografische Angaben

Abstract

Introduction: This study aimed to investigate the effects of GLP-1 receptor agonists (GLP-1 RAs) on weight, metabolic, and inflammatory bowel disease (IBD) activity parameters in patients with IBD. Methods: We conducted a systematic search for studies using GLP-1 RAs in IBD patients. The primary outcomes included weight (body mass index, total body weight, total weight loss percentage [TWL%], and >5 and >10 weight loss [WL]) and metabolic parameters (lipid panel and glycated hemoglobin [HbA1c]), while IBD-activity parameters and adverse events were secondary outcomes. Results: Ten studies were included (n = 7,831). Weight parameters showed reductions, with a TWL% of −7.55% (95% confidence interval [CI]: −3.99 to −11.12), with 60% achieving WL >5% (95% CI: 53 to 67) and 40% achieving WL >10% (95% CI: 33 to 47). Metabolic parameters showed improved and stabilized levels, of which LDL decreased from 94.96 mg/dL (95% CI: 79.91 to 110.00) to 90.45 mg/dL (95% CI: 81.58 to 99.33), and HbA1c, in diabetics, from 7.11% (95% CI: 6.62 to 7.59) to 6.76% (95% CI: 6.35 to 7.16). GLP-1 RAs seem not to exacerbate IBD activity, with improved fecal calprotectin from 289.46 μg/g (95% CI: 62.88 to 516.04) to 210.59 μg/g (95% CI: 75.45 to 345.73), with 11% and 6% requiring IV steroids and advanced therapy, respectively. Adverse events occurred at lower rates, with nausea/vomiting being the most common. Conclusion: Our findings suggest that GLP-1 RAs may be promising for reducing weight and improving metabolic parameters without exacerbating activity, and may be a safe option for IBD patients. However, larger randomized controlled trials are needed to assess causal inference and long-term effects.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →